Q-omics provides the consensus-scored NNAT profile across patient tissues and cancer cell-line models. NNAT expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, NNAT is differentially expressed in 12, with the highest sampling consensus in BLCA. Additionally, NNAT RNA expression shows 18,982 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight THCA, BLCA, and KIRP as cancer lineages where NNAT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NNAT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NNAT survival associations across molecular data types. NNAT RNA expression shows survival associations in the most cancer types (29), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NNAT RNA expression–survival associations across cancer types. High NNAT expression shows unfavorable associations in THCA, CESC, OV and LGG, but favorable associations in BRCA and SCLC. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THCA as the clearest survival context for NNAT RNA expression.
This table summarizes NNAT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for NNAT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NNAT shows lower tumor expression in BLCA, KIRC, BRCA, STAD, HNSC and UCEC. The BLCA box plot shows higher NNAT RNA expression in normal versus tumor tissue (log2 FC = −4.111, t-test p < 0.001).
This table shows molecular features associated with NNAT in patient tissues and cancer cell lines. In patient samples, NNAT shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, NNAT RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
